Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Completed 5Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Tumor-Agnostic 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 59Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 11Neoplasms 5Blast Crisis 4Recurrence 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Philadelphia Chromosome 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Sarcoma 1Piebaldism 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × nilotinib × Clear all
NCT02379416 2026-04-21

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

NCT07138378 2025-08-22

XS003-11

Xspray Pharma AB

Phase 1 Completed
128 enrolled
Tumor-Agnostic

Neoplasms

NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Novartis

Phase 2 Completed
15 enrolled 7 charts
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT01289028 2017-01-02

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Novartis

Phase 3 Completed
125 enrolled 11 charts
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Novartis

Phase 1 Completed
14 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡